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Abstract: 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is utilized in the formulation of 
pharmaceutical products and recently orphan designation was granted for the treatment of 
Niemann–Pick disease, type C. The exact mechanism of HPBCD action and side effects are not 
completely explained. We used fluorescently labelled hydroxypropyl-beta-cyclodextrin (FITC-
HPBCD) to study its pharmacokinetic parameters in mice and compare with native HPBCD data. 
We found that FITC-HPBCD has fast distribution and elimination, similar to HPBCD. Interestingly 
animals could be divided into two groups, where the pharmacokinetic parameters followed or did 
not follow the two-compartment, first-order kinetic model. Tissue distribution studies revealed, that 
a significant amount of FITC-HPBCD could be detected in kidneys after 60 min treatment, due to 
its renal excretion. Ex vivo fluorescent imaging showed that fluorescence could be measured in lung, 
liver, brain and spleen after 30 min of treatment. To model the interaction and cellular distribution 
of FITC-HPBCD in the wall of blood vessels, we treated human umbilical vein endothelial cells 
(HUVECs) with FITC-HPBCD and demonstrated for the first time that this compound could be 
detected in the cytoplasm in small vesicles after 30 min of treatment. FITC-HPBCD has similar 
pharmacokinetic to HPBCD and can provide new information to the detailed mechanism of action 
of HPBCD. 
Keywords: hydroxypropyl-beta-cyclodextrin; pharmacokinetics; HUVECs; endocytosis; 
fluorescence 
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1. Introduction 
2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is widely utilized as pharmaceutical excipient in 
several products. On the other hand, orphan designation (EU/3/11/895) was granted by the European 
Commission for hydroxy-propyl-beta-cyclodextrin for the treatment of Niemann–Pick disease, type 
C (NPC) in 2011 [1]. Between 2013 and 2015, a non-randomized, open-label, phase 1–2 trial was 
conducted to establish the safety and efficacy of lumbar intrathecal HPBCD in patients with NPC1 
[2]. The result of the study showed, that HPBCD slowed disease progression with an acceptable safety 
profile. Indeed, HPBCD is listed in the Food and Drug Administration’s (FDA) list of inactive 
pharmaceutical ingredients [3] and a previous publication showed, that intravenously (i.v.) 
administration of HPBCD is safe and well tolerated [4,5]. HPBCD is always a mixture of isomers with 
various degrees of substitution (DS), which may influence the complexation ability of the 
cyclodextrins [6]. We also tested the cytotoxicity and hemolytic activity of HPBCD with different DS 
and found no toxicity on Caco-2 cells and low hemolytic activity [6,7]. Pharmacokinetic studies of i.v. 
HPBCD revealed fast elimination and distribution over the extracellular fluid. I.v. HPBCD is 
eliminated by glomerular filtration from the blood and had only reversible vacuolation in kidneys 
but did not cause kidney dysfunction in animals or humans [4,5]. However, earlier studies reported 
that subcutaneous long-term administration of HPBCD at a daily dose of 200 mg/kg caused bone loss 
in rats [8], 2 week 0.25–0.5 g/kg/infusion of HPBCD caused inflammatory changes in the lung of 
treated pigs [9] and foamy macrophage infiltration of the lung after 4–7 days 225 mg/kg/day i.v. in 
rats [4]. Ototoxicity is another reported risk [10], which was found in cats [11] mice [12,13] and in 
humans [2], but the mechanism of ototoxicity is unknown [10]. It was also revealed using fluorescent 
cyclodextrin derivatives, that HPBCD (and other cyclodextrins) is able to enter the cytoplasm of 
different cell types by endocytosis [14–18]. This process can be essential for the effects of HPBCD. The 
pharmacokinetic of native HPBCD after different routes of administration was characterized in 
animal models and in humans [19,20], but to discover the exact mechanism of action at the level of 
tissues and cells, sensitive methods are required. Radiolabeling of cyclodextrins [21] and covalent 
conjugation of fluorophores to the cyclodextrin ring are possible tools for detection [22]. Fluorescent 
HPBCD derivatives can be applied to study the behavior of HPBCD at the level of tissues and cells 
and may help to understand its effects and side effects. We aimed to reveal the pharmacokinetic 
parameters and tissue distribution of FITC-HPBCD in mice, administered intravenously and 
compare the data of HPBCD available in the literature. We also investigated the interaction of FITC-
HPBCD with human endothelial cells, which constitute the first barrier in the body after i.v. 
administration of drugs. 
2. Materials and Methods 
2.1. Materials 
6-deoxy-6-[(5/6)-fluoresceinylthioureido]-(2-hydroxypropyl)-β-cyclodextrin (FITC-HPBCD) 
was synthesized on the analogy of rhodaminyl HPBCD as described earlier [23]. FITC-HPBCD was 
the product of Cyclolab Ltd. (Budapest, Hungary). FITC-HPBCD product number: CY-F-2005.1, 
average degree of substitution (DS) determined by NMR were DS = 0.7 for FITC and DS = 4.1 for 
hydroxypropyl groups. FITC-HPBCD was purified by extensive dialization to remove impurities. 
Free dye and 6-deoxy-6-monoamino-HPBCD contents were tested by capillary electrophoresis (CE) 
and were below the limit of detection. All other reagents were from Sigma-Aldrich (Budapest, 
Hungary). 
2.2. Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were removed from umbilical veins by 
exposure to dispase (0.2% in Hank’s balanced salt solution) and cultured in gelatin-coated flasks in 
medium 199 containing 15% foetal bovine serum (FBS), antibiotics, L-glutamine, sodium pyruvate 
and endothelial cell growth supplement from bovine pituitary [24]. For the fluorescent microscopic 
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experiments, cells were seeded onto gelatin-coated round glass coverslips and maintained in medium 
until the treatments. 
2.3. Intracellular FITC-HPBCD Accumulation in HUVEC Cells 
2.3.1. Fluorescence Microscopy 
HUVECs, cultured on gelatin-coated glass coverslips were washed twice with Hank’s Balanced 
Salt Solution (HBSS) and treated with 50 µM FITC-HPBCD for 30 min at 37 °C. Cells were washed 
five times with ice-cold HBSS and fixed with 3% paraformaldehyde for 15 min. After fixation cells 
were washed with HBSS and the nuclei were stained with Hoechst 33,342 at the final concentration 
of 300 nM. Cells were washed again and mounted on microscope slides. Samples were observed with 
a Zeiss Axio Scope.A1 fluorescence microscope (HBO 100 lamp) (Carl Zeiss Microimaging GmbH, 
Göttingen, Germany). Images were analyzed with ZEN 2012 v.1.1.0.0. software (Carl Zeiss 
Microscopy GmbH, Göttingen, Germany) 
2.3.2. Flow Cytometry 
In the flow cytometry experiments, HUVECs were treated with 50 µM FITC-HPBCD for 30 min 
at 37 °C and washed five times with ice-cold HBSS. Half of the samples were incubated for a further 
60 min in HBSS at 37 °C. After the above-mentioned incubations every sample was trypsinized, the 
cell suspensions were washed twice with ice-cold HBSS and analyzed with a FACScan flow 
cytometer (BD Biosciences, San Jose, CA, USA). Propidium-iodide (PI) (2 µg/mL) was added to the 
samples to recognize dead cells and exclude them from the evaluation. FITC-HPBCD was excited by 
an argon laser at 488 nm and the emission was detected via 530/30 nm band pass filter. Data were 
analyzed by BDIS Cellquest software (Becton-Dickinson). The cellular fluorescence intensities of the 
FITC-HPBCD treated cells were compared to the fluorescence of the untreated control cells and 
expressed as relative cellular fluorescence intensities. 
2.4. In Vivo Pharmacokinetic Investigation 
Twelve BALB/c male mice (23–25 g) were involved in the study. 0.25 mg FITC-HPBCD, 
dissolved in 0.2 mL saline solution was injected into the lateral tail vein of each mouse. Blood samples 
were collected from the orbital sinus from six mice after 1, 15, 30 and 60 min and at 1, 15, 45 and 60 
min from other six mice by the same sampling method. Blood samples were incubated for 1 h at 37 
°C and centrifuged for 8 min at 1700 rpm to separate blood plasma. Aliquots of plasma from the 
samples were placed into black 96-well plates and their fluorescence intensities were measured by a 
FLUOstar Optima microplate reader (BMG LABTECH, Offenburg, Germany; 492 nm excitation and 
520 nm emission wavelengths) and the plasma FITC-HPBCD concentrations were calculated. Using 
these data, the main pharmacokinetic parameters were determined: rate constants of elimination (ke) 
and compartmentalization (kc), volume of distribution (Vd), clearance (CL) and half-life (t1/2): 
         𝑡ଵ/ଶ = ୪୬ (ଶ)௞೐          (1) 
𝐶𝐿 = 𝑘௘ × 𝑉ௗ         (2) 
The two compartment model was characterized by the following equations: 
 
𝐶௧ = 𝐶ᇱ × 𝑒ି௞೎×௧ + 𝐶ᇱᇱ × 𝑒ି௞೐×௧       (3) 
𝐶଴ = 𝐶ᇱ + 𝐶ᇱᇱ            (4) 
where ke is the elimination rate constant of FITC-HPBCD determined from data of the terminal phase 
(ke(30-60 min) or ke(45-60 min)); t1/2 is the half-life of FITC-HPBCD calculated from the corresponding ke values; 
CL is the clearance of FITC-HPBCD; Vd is the volume of distribution of FITC-HPBCD determined 
from data related to the first minute (Vd1); Ct is the plasma concentration of FITC-HPBCD at “t”; C’ 
and C” are the two components of the initial plasma concentration of FITC-HPBCD representing the 
amount of FITC-HPBCD that will be compartmentalized and eliminated, respectively. 
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After the last blood sample collection, six animals were anaesthetized, and their blood vessels 
were perfused by warm saline solution. Finally, all mice were sacrificed, and the organs were 
removed from the six saline-perfused mice for further analysis. The collected organs (livers, lungs, 
kidneys, spleens, hearts and brains) were homogenized by adding 0.8 mL saline solution and the 
homogenates were centrifuged at 10,000 rpm for 20 min at 4 °C. From each sample, 0.1 mL of 
supernatant was placed into black 96-well plates and the fluorescence intensities were measured by 
microplate reader as described above. The lower limit of quantification of FITC-HPBCD in mouse 
plasma and organ homogenates was 0.25 µg/mL. The protein content of the tissue samples was 
determined by PierceTM BCA protein assay (Thermo Scientific, Rockford, IL, USA) according to the 
manufacturer’s instruction. FITC-HPBCD content of the samples was normalized to the tissue protein 
content. The animals were maintained in accordance with the Guidelines for the Care and Use of 
Laboratory Animals; experiments were approved by the Animal Care Committee of the University 
of Debrecen (permission no. 12/2014). 
2.5. In Vivo Fluorescence Imaging Experiments 
Male BALB/c mice (22–25 g) were bred and maintained in normal watering and feeding 
conditions in a Laboratory Animal Husbandry Facility, equipped with IVC (individually ventilated 
cages), controlled atmosphere-temperature, humidity and lighting (Vasile Goldis Western 
University, Arad, Romania). All experimental procedures were performed in compliance with the 
appropriate laws and institutional guidelines, and were approved by the Institutional Ethics 
Committee of Vasile Goldiș Western University of Arad (Arad, Romania). FITC-HPBCD (0.5 and 2.5 
mg), dissolved in 0.1 mL saline solution was injected into the femoral vein of mice under general 
anaesthesia. Maintaining the surgical plane of anesthesia, mice were placed into an in vivo imaging 
system (In-vivo Xtreme, Carestream, Carestream Health Inc. USA). At 5, 15, 30, 45 and 60 min, 
fluorescence and X-ray images were recorded of the animals. After 30 or 60 min, the blood vessels of 
some animals were perfused by warm saline solution and their organs (livers, lungs, kidneys, spleens 
and brains) were removed for ex vivo imaging (excitation: 480 nm, emission: 535 nm). 
2.6. Statistical Analysis 
SigmaStat software (version 3.1, SPSS Inc.) was used for statistical analysis. Data are expressed 
as means ±SD. Comparison of groups was perfomed by ANOVA. Differences were considered 
significant at p < 0.05. 
3. Results 
3.1. In Vivo Pharmacokinetic Investigation 
At first, our aim was to find the best model for the pharmacokinetics of FITC-HPBCD and 
determine its pharmacokinetic parameters. We applied two experimental protocols. In the first case, 
we took blood samples from the animals at 1, 15, 30 and 60 min, and in the second case, at 1, 15, 45 
and 60 min. When data of FITC-HPBCD were evaluated, the two-compartment model with the 
assumption of first-order elimination kinetics showed the best fit. During the calculation of the rate 
constants of elimination (ke) and compartmentalization (kc), we identified two distinct groups of 
animals. In the first group (Group F), a kc value greater than ke could be computed (so, the behavior 
of FITC-HPBCD in the animals of Group F was consistent with expectations resulted from the two-
compartment, first-order kinetic model) (Table 1. and Fig. 1. A and C). However, in the second group 
(Group NF), kc could not be determined (thus, the fate of FITC-HPBCD did not follow expectations 
of our model) (Table 1. and Fig. 1. B and D). Interestingly, both groups contained six mice, 
irrespectively of the sampling protocol used. 
Table 1. Pharmacokinetic parameters of 6-deoxy-6-[(5/6)-fluoresceinylthioureido]-(2-
hydroxypropyl)-β-cyclodextrin (FITC-HPBCD), administered intravenously to mice. 
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  Group F Group NF   Group F Group NF 
Dose (µg) 250 250 Dose (µg) 250 250 
t1/2 (1–15 min) 7.82 ± 1.48 6.13 ± 0.78 t1/2 (1–15 min) 7.5 ± 1.13 6.50 ± 0.31 
t1/2 (15–30 min) 7.54 ± 0.52 35.01 ± 10.15 t1/2 (15–45 min) 13.55 ± 1.45 13.36 ± 3.05 
t1/2 (30–60 min) 122.3 ± 109.4 16.61 ± 7.12 t1/2 (45–60 min) 20.06 ± 3.89 8.99 ± 4.54 
ke (1–15 min) 0.092 ± 0.023 0.115 ± 0.017 ke (1–15 min) 0.095 ± 0.017 0.107 ± 0.006 
ke (15–30 min) 0.092 ± 0.007 0.022 ± 0.009 ke (15–45 min) 0.052 ± 0.007 0.054 ± 0.013 
ke (30–60 min) 0.022 ± 0.029 0.049 ± 0.020 ke (45–60 min) 0.036 ± 0.008 0.095 ± 0.044 
kc (1–15 min) 0.109 ± 0.026 nd kc (1–15 min) 0.142 ± 0.033 nd 
Vd (mL) 4.86 ± 0.21 4.70 ± 1.27 Vd (mL) 6.25 ± 0.77 7.01 ± 0.81 
CL (mL/min) 0.11 ± 0.15 0.25 ± 0.15 CL (mL/min) 0.23 ± 0.08 0.69 ± 0.38 
Group F: pharmacokinetic parameters followed the two-compartment, first-order kinetic model. 
Group NF: pharmacokinetic parameters did not follow the two-compartment, first-order kinetic 
model. Vd: Volume of distribution at 1 min. CL: clearance. nd: kc values in Group NF could not be 
determined. 
 
Figure 1. Plasma concentration curves of FITC-HPBCD after i.v. administration in mice. Sampling 
times 1, 15, 30 and 60 min (A and B; n = 6) and 1, 15, 45 and 60 min (C and D; n = 6). A and C followed 
the first-order elimination kinetic, while B and D did not follow it. 
FITC-HPBCD showed fast elimination in mice after i.v. administration. Within 60 min 96.58 ± 
2.6% (n = 12) of the i.v. administered FITC-HPBCD was eliminated from mice. Despite the fast 
elimination, FITC-HPBCD showed rapid compartmentalization (confirmed by the calculation of 
volume of distribution: Vd). Vd was higher than the blood volume of mice, at the first minute, it was 
5.7 ± 1.34 mL (n = 12). There was no significant difference between Vd values of the two groups with 
different elimination parameters. Compartmentalization and elimination of the compound in 
question happened at the same time in the animals, but in the group not following the kinetic model, 
distribution appeared to be too complex for a simple interpretation. 
After 60 min of the pharmacokinetic experiment, we analyzed the tissue accumulation of FITC-
HPBCD in tissue homogenates ex vivo. The fluorescence intensities of FITC-HPBCD in the 
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supernatant of liver, lung, spleen, heart and brain homogenates were not elevated after 60 min of the 
experiment. Only the homogenates of kidneys showed significant fluorescence (Figure 2). 
 
Figure 2. FITC-HPBCD content in the supernatant of the tissue homogenates of mice. FITC-HPBCD 
was administered i.v. and after 60 min of treatment significant fluorescence intensity could be 
measured only in the supernatant of kidney homogenates (p < 0.001). 
3.2. In Vivo Fluorescence Imaging Experiments 
Two doses (0.5 mg and 2.5 mg/animal) of FITC-HPBCD were administered to the mice i.v. in the 
in vivo fluorescence imaging experiments. Images were recorded at 5, 15, 30, 45 and 60 min. In both 
cases, significant fluorescence could be observed in the animals (Figure 3, mice on the right in the 
images), compared to the control mice (Figure 3, mice on the left in the images). The compound was 
distributed over the entire body of the animals and their fluorescence intensities decreased as a 
function of time.  
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Figure 3. Representative in vivo fluorescence images of FITC-HPBCD treated mice. FITC-HPBCD (0.5 
and 2.5 mg) was injected i.v. and images were recorded at 5, 15 and 30 min after injection. Untreated 
mice can be seen on the left and FITC-HPBCD treated mice can be seen on the right in each image. 
FITC-HPBCD distributed over the entire body of mice and the in vivo fluorescence decreased as a 
function of time. 
After 30 or 60 min, animals were perfused with warm saline solution and their organs were 
removed to measure the ex vivo fluorescence intensities. In case of the 2.5 mg/animal dose, every 
organ showed higher fluorescence intensities (Figure 4, organs on the right) than the control samples 
(Figure 4, organs on the left). Kidneys had especially high fluorescence and lung showed elevated 
intensity. From the administration of 0.5 mg FITC-HPBCD, the fluorescence intensities of the 
removed organs were similar to the control when imaged together, only kidneys had relative higher 
fluorescence after 30 min. Separated examination of brains with different gains revealed that in both 
doses, the brains of the treated animals had higher fluorescence than the untreated ones after 30 min. 
After 60 min there was no difference between the organelle fluorescence of the brains, the intensity 
of the treated sample decreased to the control level.  
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Figure 4. Representative ex vivo fluorescence images of the organs of FITC-HPBCD treated mice after 
30 min treatment. Brains were examined separately from other organs after 30 and 60 min of treatment 
and imaged from beneath. The organs of untreated mice can be seen on the left in the images. Kidneys 
showed the highest fluorescence intensities in both doses (0.5 and 2.5 mg). In the case of 2.5 mg dose, 
lung also had elevated intensity. At 30 min the brains of the FITC-HPBCD treated animals had higher 
fluorescence than the controls, while after 60 min there was no difference between the fluorescence of 
the brains. 
Interestingly, lungs also showed higher ex vivo fluorescence in separated imaging after 0.5 mg 
FITC-HPBCD administration compared to the untreated control (see Supplementary Material Figure 
S1). It could be observed that FITC-HPBCD accumulated in the bladder (30 and 45 min) and then was 
urinated out (60 min) (see Supplementary Material Figure S2). 
3.3. Intracellular FITC-HPBCD Accumulation in HUVEC Cells 
3.3.1. Fluorescence Microscopy 
FITC-HPBCD could be detected in the cytoplasm of HUVECs in small green vesicles after 30 
min of incubation. Some larger, more intense vesicles could be observed around the cell nuclei (Figure 
5). In control cells, some autofluorescent vesicles could be identified. 
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Figure 5. Fluorescence microscopic images of FITC-HPBCD treated (A) and untreated (B) human 
umbilical vein endothelial cells (HUVECs). Endocytotic green vesicles can be observed in the 
cytoplasm (A), while some autofluorescent vesicles can be seen in the control cells (B). (Green—FITC-
HPBCD, blue—cell nuclei). 
3.3.2. Flow Cytometry 
To confirm cellular uptake of FITC-HPBCD by HUVECs, flow cytometric measurements were 
performed. After 30 min of incubation with FITC-HPBCD and extensive washing of cells, the cellular 
fluorescence was quantified by flow cytometer. FITC-HPBCD treatment significantly increased the 
cellular fluorescence, compared to the untreated control. Incubation of cells for 60 min in HBSS after 
30 min of FITC-HPBCD treatment significantly decreased the fluorescence of HUVECs (Figure 6). 
 
Figure 6. Flow cytometric analysis of FITC-HPBCD uptake in HUVECs. Incubation of HUVECs for 
30 min with 50 µM of FITC-HPBCD significantly increased the cellular fluorescence and a following 
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60 min washing with HBSS decreased it. (Data are expressed as means ±SD, n = 3, significance is 
expressed as **p < 0.01). 
4. Discussion 
In recent years, much attention was paid to the pharmacological and toxicological effects of 
cyclodextrins, especially to HPBCD. HPBCD is widely used excipient in oral and parenteral 
formulations, furthermore it is applied as orphan drug in the treatment of Niemann–Pick disease, 
type C. The pharmacokinetic properties of HPBCD was studied in rats [19] and humans [2,5,25], but 
the tissue distribution and the interactions with organs of this compound was moderately revealed. 
Mainly the nephrotoxicity was considered. It is known that HPBCD has extracellular distribution and 
fast elimination by glomelural filtration. FITC-HPBCD provides an excellent tool to study the above-
mentioned questions and the molecule can also be detected sensitively at a cellular level. Moreover, 
FITC-HPBCD was successfully used to monitor renal functions [26]. In our experiments, FITC-
HPBCD was administered to mice i.v. and blood samples were collected according to two protocols. 
At first, blood samples were collected at 1, 15, 30 and 60 min from six mice. Then the experiments 
were repeated by applying 1, 15, 45 and 60 min sampling times with six other animals and the 
pharmacokinetic parameters of mice varied in a relatively narrow range (Table 1). The t1/2 and ke 
values calculated from data belonging to different time periods were different, thus they showed, 
that FITC-HPBCD had no simple elimination. As FITC-HPBCD was administered i.v., the most likely 
reason of the variation of ke values was the presence of more than one compartment for FITC-HPBCD. 
ke values decreasing over time are well fitted to the characteristics of a two-compartment model. 
Among the presented ke values, the ke belonging to the terminal phase (ke (30–60 min) or ke (45–60 min)) was 
considered to be closest to the truth. Thus, this ke value was used for the calculation of CL, as CL also 
characterizes the elimination. On the other hand, FITC-HPBCD was eliminated rapidly into the urine, 
and Vd was the least biased by elimination at the first minute (Vd1), because at the beginning of the 
process compartmentalization was more significant. As a result, ke (30–60 min) or ke (45–60 min) and Vd1 were 
used for the calculation of CL. kc was also calculated from data at the first time period (kc (1–15 min)). 
The data evaluation revealed that the animals could be divided into two groups, where the 
pharmacokinetic parameters followed or did not follow the two-compartment model. Interestingly, 
the number of the animals in the group following the model was the same as in the group not 
following the model. The difference between the two groups was in the ke values. In the group not 
following the model the ke was higher than kc. The reason of this phenomenon is not known, but the 
distribution seems to be too complex. Nephrotoxicity can be excluded as a possible reason, because 
it decreases glomerular filtration and elimination rate [19]. The applied dose was approximately 10 
mg/kg, lower than used earlier in rats [19] and this dose is much below the no observed adverse effect 
levels (NOAELs) of HPBCD in rats (50 mg/kg/day) [4,27]. Pharmacokinetic data revealed that FITC-
HPBCD had fast elimination in mice, similar to HPBCD data in rats and humans. The t1/2 of FITC-
HPBCD was between 6–8 min in the first 15 min and 9–20 min in the 30–60 or 45–60 min sampling 
period. Only two animals (belonging to the group following the model) had high t1/2, causing big 
deviation. The group not following the model had lower t1/2 in the last period. Vd values showed fast 
distribution, at 1 min these were between 4.7 and 7 mL, which were higher than the expected blood 
volume of mice. The two groups had similar Vd at 1 min of sampling, it was 5.55 ± 0.98 mL (n = 6) for 
the group following the model, and 5.85 ± 1.72 (n = 6) for the group not following the model (Table 
1). It should be noted that the average Vd was 5.7 ± 1.34 mL (n = 12), which corresponds well with the 
extracellular fluid volume (5.8 ± 0.3 mL for 28.6 ± 1.2 g male mice) determined in wild-type C57BL6 
mice [28]. According to these data, FITC-HPBCD rapidly distributes over the extracellular fluid after 
i.v. administration. 
Measurement of the tissue distribution of FITC-HPBCD after 60 min of treatment showed that 
tissue accumulation could be detected only in kidneys. The major route of elimination of HPBCD is 
renal excretion and similar to earlier studies on rats with HPBCD, the target organs of FITC-HPBCD 
are kidneys in mice. Ex vivo fluorescence studies showed more details of distribution. After 30 min 
of treatment, significant fluorescence could be also detected in other organs like lung, liver and brain. 
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It is in agreement with earlier findings, where the highest HPBCD concentrations were found in 
kidneys and lung of rats and in kidneys and liver of dogs [4]. Recently, we also found relatively 
higher 68Ga-NODAGA-HPBCD activity in the lung after 30 min compared to other organs [21]. 
Interestingly, we found FITC-HPBCD fluorescence in the brain after 30 min, which decreased to the 
control level at 60 min in accordance with the tissue distribution result. In experiments carried out 
with [14C]-HPBCD on wild type BALB/c (Npc1+/+) mice and Npc1−/− mice, it was found that the Vd 
at 2 min available to HPBCD exceeded the plasma and vascular volume of the brain, indicating a 
significant binding of HPBCD to the brain vasculature without crossing of the blood–brain barrier 
(BBB) [29]. The interaction of FITC-HPBCD and endothelial cells can explain the fluorescence of the 
brain, without BBB penetration. The molecular structure, hydrophilicity and high molecular weight 
predict that cyclodextrins do not penetrate biological membranes [30]. However, we recently showed 
that fluorescent cyclodextrins are able to enter Caco-2 intestinal epithelial cells by endocytosis [14,15]. 
To test the possible interactions of FITC-HPBCD with endothelial cells we treated HUVECs with this 
compound and investigated the cellular fluorescence. We found for the first time, that FITC-HPBCD 
localized in the cytoplasm of HUVECs in small endocytic vesicles after 30 min treatment. On the 
fluorescence microscopic images, numerous small vesicles can be observed in the cytoplasm of the 
treated cells. Interestingly, some autofluorescent vesicles can also be seen in the control cells. The 
autofluorescence of HUVECs was reported by other studies, but its origin is unknown [31]. The 
internalization and increase of cellular fluorescence were confirmed by flow cytometry. After 60 min 
incubation of FITC-HPBCD loaded cells with HBSS, the fluorescence was markedly decreased, but 
not completely. This indicates that endothelial cells can take part in the distribution of FITC-HPBCD 
in the body, but on the other hand, the endocytosis of FITC-HPBCD should be confirmed by other 
types of endothelial cells, like brain capillary endothelial cells. 
Limitations of the study: The in vivo fluorescence imaging experiments were not suitable to 
detect the real-time organ distribution of FITC-HPBCD in mice. FITC-HPBCD in the highly perfused 
skin capillaries gives a strong fluorescence signal from the skin of the animals, obscuring the signal 
of the organs from the deeper layer. Ex vivo organ measurements were needed to reveal the organ 
distribution of FITC-HPBCD. 
5. Conclusions 
In conclusion FITC-HPBCD has similar pharmacokinetic properties to HPBCD, although we 
found some deviation from the applied two-compartment model. It should be noted that we tested 
this molecule on mice, while the available data originates from other species. The fast elimination, 
similar t1/2, Vd and tissue distribution show that FITC-HPBCD could be a suitable alternative model 
molecule to study and understand the pharmacological effect of HPBCD. The higher distribution in 
the lung can explain the pulmonary side effects of HPBCD, but on the other hand it may help to 
develop new targeting strategies. The great advantage of FITC-HPBCD is the easy, simple and 
sensitive detection, compared to HPBCD. The applied fluorescent technology can also help to test 
new cyclodextrin derivatives for targeted therapy. In addition, further studies are needed to test other 
administration routes. 
Supplementary Materials: The following are available online www.mdpi.com/2218-273X/9/10/509/s1. Figure S1: 
Ex vivo fluorescence of the lung, 60 min after the i.v. administration of 0.5 mg FITC-HPBCD. Figure S2: In vivo 
fluorescence and X-ray imaging of FITC-HPBCD treated mice.  
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